Navigation Links
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Date:6/11/2008

Patients Receiving Every Four-Week Subcutaneous Golimumab Also Experienced

Improvements in Physical Function and Disease Activity

PARIS, June 11 /PRNewswire/ -- Findings from two new Phase 3 studies showed that patients receiving every four-week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg and weekly methotrexate (MTX) experienced significant improvements in the signs and symptoms of rheumatoid arthritis (RA) as well as in physical function and disease activity, with some patients achieving remission as measured by Disease Activity Score (DAS28). Findings from two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies showed the efficacy of golimumab in two important populations - MTX-naive patients and patients with active RA despite ongoing treatment with MTX. These data were presented at the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology. Golimumab is currently in the most comprehensive initial Phase 3 development program to date for an anti-tumor necrosis factor (TNF)-alpha biologic therapy with ongoing studies for the treatment of RA, psoriatic arthritis and ankylosing spondylitis.

In the study, GOlimumab FOR subjects With Active RA Despite MTX (GO-FORWARD), both the 50 mg and 100 mg doses of golimumab were studied in patients whose disease was active despite ongoing treatment with MTX. At week 14, 55 percent of patients receiving golimumab 50 mg plus MTX and 56 percent receiving golimumab 100 mg plus MTX achieved at least 20 percent improvement in signs and symptoms of RA (ACR 20), compared to 33 percent of patients receiving placebo and MTX (p<0.01 and p<0.001, respectively). Improvements were seen as early as first clinical assessment, which was four weeks after the first golimumab injection, and generally continued to improve over time.

"The data in this study demonstrate that golimumab is beneficial in improving numerous disease parameters, including in
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) a ... patent-pending technologies poised to redefine how consumers receive energy, medicines, ... business update teleconference and webcast for shareholders and the investment ... PM ET. Fuse Science, Inc. CEO, ... will be joined by Rubin Hanan , ...
(Date:5/17/2013)... , May 17, 2013  Atossa Genetics, Inc. (NASDAQ: ... that Kyle Guse , Chief Financial Officer ... LLP MicroCap Conference on Thursday, May 30, 2013, in ... Hotel. The Company,s presentation is scheduled to ... a live webcast. To access the webcast, go to ...
(Date:5/17/2013)... BEIJING , May 17, 2013 Sinovac Biotech ... vaccines in China , today announced that ... quarter ended March 31, 2013, before market on Tuesday, May ... Tuesday, May 28, 2013, at 8:00 a.m. EDT (May 28, ... Company,s financial results and provide an update on recent corporate ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3
... to be Dosed Shortly -, SAN DIEGO, March ... completion of the safety and,tolerability assessment of its third ... new HspE7 (HspE7 + Poly-ICLC) in patients with cervical,intraepithelial ... and met the limits prescribed in the trial protocol, ...
... will remain open until March 21, 2008, ... as,government agencies when implementing new policies, a national ... today,called for public comment on a series of ... trials., As part of the four year ...
Cached Medicine Technology:Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 5EDICT Opens Public Comment Period for Clinical Trials Policy Recommendations 2
(Date:5/18/2013)... Pomona, NY (PRWEB) May 18, 2013 Dr. ... sleep apnea dentistry, employs his knowledge of the ... in sleep apnea patients. With May being Better Sleep Month, ... have some sort of chronic sleep disorder, and sleep apnea ... With sleep apnea, a person will essentially stop breathing at ...
(Date:5/18/2013)... May 18, 2013 John Ravera, D.D.S., a ... addition of a new member to his dental team, Courtney ... in the field for over 10 years. She received her ... and was elected a member of Sigma Pi Alpha, a ... Marino enjoys working with patients of all ages, helping them ...
(Date:5/18/2013)... 2013 According to the the Stevens Johnson ... Epidermal Necrolysis, is a severe allergic reaction usually to medicine ... but it can quickly advance causing blistering and large areas ... death. SJS can develop at any time and seriously ... NBA player, Manute Bol, passed away after he received kidney ...
(Date:5/18/2013)... The product liability attorneys at Wright & Schulte have ... nationwide who have sustained serious tendon injuries allegedly caused by ... all part of MDL 2308 and were all filed on ... heard in the U.S. District Court of the Western District ... specializes in defending the rights of those who have suffered ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Daily Gossip announced ... with the creator of the Program Yourself Thin ... on their online website by the end of the month ... accomplish to successfully reeducate themselves and lead a healthy lifestyle, ... Program Yourself Thin package is available for only $97 ...
Breaking Medicine News(10 mins):Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 2Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 3Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2Health News:Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 3Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 4Health News:Program Yourself Thin Review and Secrets Revealed By Daily Gossip Magazine 2
... its key inflammatory mediators (IL-12 and IL-23) is highly ... researchers. ,Current treatments for psoriasis include ... symptoms of the disease. Many of these treatments are ... very effective, according to Gerald Krueger, M.D., principal investigator ...
... extreme losses -- in two cases, greater than $100,000 -- ... been linked to a class of drugs commonly used to ... Mayo Clinic study is the first to describe this compulsive ... that stimulate dopamine receptors in the brain. ,The ...
... A botched up family planning operation would have claimed one ... of Indian origin// wasn't there to perform a lifesaving surgery. ... 300 km from here, was a boon for Vijayanti Devi, ... was cut out by mistake during a routine family planning ...
... set to start its manufacturing facility in the ... drug market. ,Ind-Swift Laboratories has completed ... its Clarithromycin active pharmaceutical ingredient (API) manufacturing unit, ... ,Clarithromycin is a macrolide antibiotic molecule ...
... diagnosis laboratories and counselling centres in various hospitals as HIV ... ,The decision was announced at the second meeting of the ... UNB reported. ,The meeting, chaired by health advisor ... policy, said a press release. ,The meeting decided ...
... of diseases or disorders of the valves in the heart ... caused by diseases such as rheumatic fever, or degenerative// conditions ... for valvular heart disease (VHD) highlight the need for improvement ... chair of the European Society of Cardiology (ESC) task force ...
Cached Medicine News:Health News:New Treatment For Psoriasis Is Highly Effective 2Health News:Medications for Restless Legs Syndrome may Trigger Compulsive Gambling 2Health News:Medications for Restless Legs Syndrome may Trigger Compulsive Gambling 3Health News:New Guidelines for VHD 2Health News:New Guidelines for VHD 3Health News:New Guidelines for VHD 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: